



ImmuCast™ Release Notes
v5.25.5

Prepared by STChealth
March 8, 2021

STChealth
411 South 1st Street
Phoenix, AZ 85004
480.745.8500 phone
602.598.7712 fax
www.STChealth.com

Support Services

For general support on this product, contact your system administrator or help desk. For up-to-date documentation, visit the STC Documentation Portal at <https://documentation.stchome.com/>.

Connect with Us on Social Media



Sign up for our
NEWSLETTER



Copyrights and Trademarks

© 2019 by Scientific Technologies Corporation (STC). All rights reserved.

This documentation describes the following: ImmuCast 5.25.5 (and IWeb Forecaster) release notes

No part of this publication may be altered, reproduced, transmitted, stored in a retrieval system, or translated into any human or computer language, in any form or by any means, electronic, mechanical, magnetic, optical, or otherwise, without the prior written permission of the copyright owner.

This document, along with any embedded media, is provided for informational purposes only. Scientific Technologies Corporation (STC) provides this material “as is” and does not assert that this document is error free. The information contained herein may not necessarily accurately represent the current or planned functions of the application and may be subject to significant and frequent modification. Scientific Technologies Corporation (STC) may change this document, any embedded content, and the product described herein at any time. Any changes will be incorporated in new versions of this document.

Scientific Technologies Corporation (STC) recognizes the rights of the holders of all trademarks used in its publications.

This document may provide hyperlinks to third-party websites or access to third-party content. Links and access to third-party sites are provided for your convenience only. Scientific Technologies Corporation does not control, endorse, or guarantee third-party content and is not responsible for any content, associated links, resources or services associated with a third-party site. Scientific Technologies Corporation shall also not be liable for any loss or damage associated with your use of any third-party content. ⁽²⁰¹⁸¹²¹²⁾



Table of Contents

Introduction	4
Apply the Release	4
For ImmuCast 1.0 (Stand-Alone Forecaster)	4
Patient Groups Affected by this Release (v5.25.5)	4
New Features/Improvements	5
Issue Summary	5
Details for v5.25.5	7
Product Documentation	8

Introduction

Detailed descriptions and test cases (if applicable) follow below in the ticket descriptions. This release may contain immunization schedule changes that affect the group of patients you select to be re-forecasted. Please refer to the section entitled "Patient Groups Affected by this Release" for guidance on determining if patients should be reforecast.

Also note that Forecast, Forecaster, and ImmuCast are used interchangeably throughout this document.

Apply the Release

Apply the release by executing either the included forecast.bat or forecast.sh file. Prior forecast releases through version 5.25.4 should have already been applied. Log files, which are created in the same folder from where the release is executed, can be reviewed for errors. To determine the current version of ImmuCast, execute this statement from SQLPlus:

```
SQL> select max(version) from h33_forecast_version where insert_stamp = (select max(insert_stamp) from h33_forecast_version);
```

If the version number returned is not 5.25.4 or higher, download and apply the previous releases prior to applying this release. Log files are created in the folder from where the release is executed and can be reviewed for errors.

For ImmuCast 1.0 (Stand-Alone Forecaster)

After applying the release, restart Tomcat to enable and cache new vaccine codes into memory.

Patient Groups Affected by this Release (v5.25.5)

This release adds the Ebola Vaccine Group and CVX 204 - Ebola Zaire vaccine, live for CDSi compliance and ImmuCast 2.0 forecasting. Forecasting logic is also added for the Janssen (J&J) COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL (CVX 212) vaccine.



New Features/Improvements

The following are new features, functionalities, or enhancements in this release. NOTE: Special Indications are only available to ImmuCast 2.0.

Issue Summary

New Vaccine Group

Family Code	Description
34	Ebola

CVX and CPT Code Updates

CVX	CPT	CDC Short Description
204	N/A	Ebola Zaire vaccine, live

Ebola Contraindications and Observation Codes

The following contraindications for Ebola have been added for IWeb.

Description
Severe allergic reaction after previous dose of ebola
Severe allergic reaction to rice protein
Severe allergic reaction (e.g., anaphylaxis) to a vaccine component

Ebola Special Indications (Available for ImmuCast 2.0 only.)

The following special indications for Ebola have been added to support ImmuCast 2.0

Description
Ebola virus outbreak response (182)
Health care personnel at federally designated Ebola treatment center in U.S. (183)
Laboratorians or other staff at biosafety level 4 facilities in U.S. (184)

**Janssen (J&J) COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL (CVX 212)****Description**

[Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States.](#)

Addition of CVX 212, Janssen (J&J) COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL as a 1 dose schedule. If patient has received either Pfizer or Moderna COVID-19 vaccine as Dose 1, CVX 212 will mark patient as complete for COVID series.

CVX	Short Description	CDC Product Name
208	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose	Pfizer-BioNTech COVID-19 Vaccine
207	COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose	Moderna COVID-19 Vaccine
212	COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL	Janssen (J&J) COVID-19 Vaccine
213	SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED	

New COVID-19 Contraindications

The following are new contraindications for COVID-19 which have been added for IWeb.

Contraindication	Product
Allergic reaction to polysorbate 80	Janssen (J&J) COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL (CVX 212)
Known allergy to Polyethylene glycol [PEG]	Moderna COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose (CVX 207) Pfizer-BioNTech COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose (CVX 208)



Details for v5.25.5

The following lists detailed test case information for COVID-19 immunization forecasting.

Key	Vaccine Group	Description						
		Refer to Issue Summary above						
Test Scenario		Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comment
No prior Covid-19 vaccine history and current age > 16 years of age.	DOB: 01/01/1980	COVID-19			12/12/2020	12/12/2020	01/08/2021	Rec date is EUA date of 12/12/2020
Test Scenario		Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comment
No prior Covid-19 vaccine history and current age < 16 years of age.	DOB: 01/01/2005	COVID-19			01/01/2021	01/01/2021	01/28/2021	Rec date is 16 th birthday
Test Scenario		Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comment
Current age >= 18 years of age with administration of Dose 1	DOB: 01/01/1980	COVID-19 (CVX 212)	03/01/2021	Y				Complete
Test Scenario		Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comment
Current age >= 18 years of age with administration of Dose 1 Moderna and Dose 2 Janssen (J&J) administered	DOB: 01/01/1980 COVID-19 (CVX 212)	COVID-19 (CVX 207)	12/12/2020	Y	01/09/2021	01/09/2021	02/05/2021	
		COVID-19 (CVX 212)	03/01/2021	Y				Complete
Test Scenario		Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comment
Current age > 18 years of age with administration of Dose 1 and Dose 2 Janssen (J&J).	DOB: 01/01/1980 COVID-19 (CVX 212)	COVID-19 (CVX 212)	03/01/2021	Y				Complete
		COVID-19 (CVX 212)	03/28/2021	Y				Patient Complete with Dose 1. Dose 2 marked as "Extraneous dose."



Product Documentation

Product documentation is located on the STC Documentation Portal: <https://documentation.stchome.com/>.
The following documents are available for this version of ImmuCast:

- Implementation and Configuration Guide 5.18.8
- ImmuCast 5.25.5 Release Notes